Éleuthère Irénée du Pont de Nemours started out as the sole manufacturer of gunpowder and explosives to the Crown in late 18th-Century France, the son of minor nobility. Their connection to royalty did not serve the DuPont family well in the wake of the French Revolution. Fleeing to the United States in 1799, DuPont established a new company. Over the next two centuries, Éleuthère's descendants and the company he founded have achieved levels of wealth, power and influence that his father (personal physician to King Louis XV's mistress, Madame de Pompadour) could not have imagined.
A decision by the United States Supreme Court saw through all the BP smoke and mirrors, denying the oil company’s petition for review, and leaving intact a landmark settlement for the people and businesses of the Gulf Coast, arising out of the disastrous 2010 spill.
If anyone had any doubt about what BP intended, you only need to look at one exchange between attorney Mike Juneau, on behalf of the Claims Administrator, and BP:
Earlier this year, the U.S. Food and Drug Administration, medical authorities in the E.U. and Health Canada approved the controversial asthma drug, Xolair, for the treatment of hives, or urticara, a painful skin condition marked by pink, itchy rashes. This drug has been implicated in an increased risk of suffocation from anaphylaxis (a blockage of the air passage caused by throat swelling among other side effects). Drug makers Genentech and Novartis are finding that approval for this purpose in Great Britain is not quite as easy, however.
As professional baseball player Yogi Berra once said, “It's deja-vu all over again.”
In November of 2013, a research study, carried out at a Veteran's Administration facility, appeared in the Journal of the American Medical Association. The conclusion:
“Among a cohort of men in the VA health care system who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of adverse outcomes” (Vigen, et. al.)
In other words, the use of supplemental testosterone appeared to be connected with heart attacks among the research subjects.
Under normal circumstances, a hysterectomy – the surgical removal of a woman's uterus – is a fairly routine procedure. Though it is major surgery that entails a certain amount of risk and requires a convalescent period of up to five days, complications are relatively rare.
Hip implants from Smith and Nephew are causing destruction of tissue and bone, which makes Levin Papantonio attorney Ben Gordon want to hear the company say, “Uncle.” The metal-on-metal implants are among a series of bad products put out by Smith and Nephew. Ben Gordon will see the implant company in court in the manufacturer’s home base of Memphis, Tennessee where a settlement has yet to be reached.
“[Smith and Nephew] is denying everything. They are claiming that their product is still the best on the market,” says Gordon.
According to legend, the half-mad Emperor Nero played his fiddle while the Eternal City was being consumed by flames. This story has little basis in historical fact (first, Nero actually did take some action to contain the fires raging in the city, and secondly, the fiddle wasn't invented until some 10 centuries later), but it serves as an apt metaphor for modern America – particularly when it comes to medical products that are causing injury and death and a corrupt government so beholden to corporate interests that it fails to regulate in any meaningful way.
For patients who have received a hip replacement, the outcome expected may be to move easier and without pain. For the recipients of a Stryker ABG II or Rejuvenate hip implant, however, the new outcome may be a settlement of $300,000. The Stryker implants were documented to cause corrosion, illness, pain and swelling, and even metal debris found in victims’ blood. They were recalled in 2012.
As of the end of October, there have been in excess of 50,000 vaginal mesh lawsuits filed against manufacturers of these devices – yet a recent study published in the British Medical Journal suggests that this treatment for stress urinary incontinence (SUI) and pelvic organ prolapse (POP) is generally regarded as safe. Earlier this year, at a meeting of the American Urological Association, it was announced that the connection between the mesh and the painful symptoms suffered by these women was “unclear.” Nonetheless, the number of revision surgeries to remove the mesh is increasing.